Ginkgo Bioworks Holdings, Inc.

BMV:DNA * Stock Report

Market Cap: Mex$11.9b

Ginkgo Bioworks Holdings Management

Management criteria checks 3/4

We currently do not have sufficient information about the CEO.

Key information

Jason Kelly

Chief executive officer

US$262.5k

Total compensation

CEO salary percentage95.2%
CEO tenure17yrs
CEO ownership4.0%
Management average tenure6.5yrs
Board average tenure1.7yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Jason Kelly's remuneration changed compared to Ginkgo Bioworks Holdings's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$651m

Jun 30 2024n/an/a

-US$898m

Mar 31 2024n/an/a

-US$854m

Dec 31 2023US$263kUS$250k

-US$893m

Sep 30 2023n/an/a

-US$857m

Jun 30 2023n/an/a

-US$1b

Mar 31 2023n/an/a

-US$2b

Dec 31 2022US$263kUS$250k

-US$2b

Sep 30 2022n/an/a

-US$4b

Jun 30 2022n/an/a

-US$3b

Mar 31 2022n/an/a

-US$2b

Dec 31 2021US$381mUS$250k

-US$2b

Sep 30 2021n/an/a

-US$276m

Jun 30 2021n/an/a

-US$200m

Mar 31 2021n/an/a

-US$175m

Dec 31 2020US$11mUS$250k

-US$127m

Compensation vs Market: Jason's total compensation ($USD262.50K) is about average for companies of similar size in the MX market ($USD233.44K).

Compensation vs Earnings: Jason's compensation has been consistent with company performance over the past year.

CEO

Jason Kelly (43 yo)

17yrs

Tenure

US$262,500

Compensation

Dr. Jason Kelly serves as Director of Genomatica, Inc. Dr. Kelly founded Ginkgo Bioworks, Inc. (nka:Ginkgo Bioworks Holdings, Inc.) in 2008 and serves as its Chief Executive Officer and has been Director s...

Leadership Team

NamePositionTenureCompensationOwnership
Jason Kelly
Founder17yrsUS$262.50k4.03%
MX$ 480.6m
Reshma Shetty
Founder17yrsUS$262.50k4.39%
MX$ 523.1m
Mark Dmytruk
Chief Financial Officer4.2yrsUS$1.69m0.092%
MX$ 10.9m
Thomas Knight
Founderno datano datano data
Austin Che
Founderno datano data4.5%
MX$ 536.2m
Bartholomew Canton
Founderno datano data4.38%
MX$ 522.0m
Steven Coen
Chief Accounting Officer1.7yrsno data0.014%
MX$ 1.6m
Karen Tepichin
General Counsel & Secretaryno datano datano data
Anna Wagner
Senior Vice President of Corporate Developmentno datano datano data
Samantha Sutton
Head of People7yrsno datano data
Joshua Dunn
Head of Design6.3yrsno datano data
Joaquim Marques
Head of Omics & Analytical Chemistry6.5yrsno datano data

6.5yrs

Average Tenure

43yo

Average Age

Experienced Management: DNA *'s management team is seasoned and experienced (6.5 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Jason Kelly
Founder17yrsUS$262.50k4.03%
MX$ 480.6m
Reshma Shetty
Founder17yrsUS$262.50k4.39%
MX$ 523.1m
Norbert Bischofberger
Member of Biopharma Advisory Board1yrno datano data
John M. Maraganore
Member of Biopharma Advisory Board1yrno datano data
Harry Sloan
Independent Director3.3yrsUS$459.38k0.49%
MX$ 58.6m
Mark McCamish
Member of Biopharma Advisory Board1yrno datano data
Christian O. Henry
Independent Director9yrsUS$477.50k0.063%
MX$ 7.5m
Kathy Hannan
Independent Director2.4yrsUS$448.67k0.0079%
MX$ 939.8k
Christi Shaw
Member of Biopharma Advisory Board1yrno datano data
Shyam Sankar
Independent Chairman of the Board10yrsUS$485.19k0.12%
MX$ 13.8m
Jeff Legos
Member of Biopharma Advisory Board1yrno datano data
Paolo Martini
Member of Biopharma Advisory Board1yrno datano data

1.7yrs

Average Tenure

59.5yo

Average Age

Experienced Board: DNA *'s board of directors are not considered experienced ( 1.7 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/21 00:23
End of Day Share Price 2024/11/26 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Ginkgo Bioworks Holdings, Inc. is covered by 10 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Derik de BruinBofA Global Research
Michael RyskinBofA Global Research
Mark MassaroBTIG